Recent FDA Approvals (through July 2010) related to Tribenzor, Daiichi Sankyo, Aricept, Eisai and Pfizer, Daytrana, Glassia, Zuplenz, Infergen, Cuvposa
Olmesartan medoxomil, amlodipine, hydrochlorothiazide (Tribenzor, Daiichi Sankyo) was approved for the treatment of uncontrolled hypertension.
A once-daily, higher-dose donepezil HCl (Aricept, Eisai and Pfizer) 23-mg tablet was approved for the treatment of moderate-to-severe Alzheimer's disease.
Methylphenidate transdermal system (Daytrana, Shire) was approved for the treatment of attention deficit hyperactivity disorder in adolescents aged 13 to 17 years.
Ondansetron (Zuplenz, Strativa) was approved for the prevention of postoperative, highly and moderately emetogenic cancer, chemotherapy-induced, and radiotherapy-induced nausea and vomiting.
Consensus Interferon (Infergen, Three Rivers Pharmaceuticals) expanded labeling was approved to include daily use in combination with ribavirin for the retreatment of chronic hepatitis C patients.
Glycopyrrolate (Cuvposa, Shionogi Pharma) oral solution was approved for the treatment of chronic severe drooling caused by neurologic disorders in children aged 3 to 16 years.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More